
Novo Nordisk Accuses Competitor of Fraud in $13 Billion Hypertension Drug Deal: What Does This Mean for the Pharmaceutical Industry?
Novo Nordisk Sues KBP Biosciences for Alleged Fraud in Hypertension Drug Deal In a significant legal development, Novo Nordisk, the Danish pharmaceutical giant, has taken KBP Biosciences to court in Singapore, seeking up to $830 million in damages. The lawsuit stems from a 2023 agreement between the two companies, in which Novo Nordisk purchased a…